# A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

> **NCT06111521** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 35 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY3537982
- **DRUG:** Digoxin
- **DRUG:** Rosuvastatin
- **DRUG:** Midazolam
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT06111521
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-27
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06111521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06111521, "A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06111521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*